AR093843A1 - Derivados de piridina agonistas de receptores cb2 - Google Patents

Derivados de piridina agonistas de receptores cb2

Info

Publication number
AR093843A1
AR093843A1 ARP130104545A ARP130104545A AR093843A1 AR 093843 A1 AR093843 A1 AR 093843A1 AR P130104545 A ARP130104545 A AR P130104545A AR P130104545 A ARP130104545 A AR P130104545A AR 093843 A1 AR093843 A1 AR 093843A1
Authority
AR
Argentina
Prior art keywords
dioxo
oxo
cycloalkyl
alkyl
phenylalkyl
Prior art date
Application number
ARP130104545A
Other languages
English (en)
Inventor
Frei Beat
Gobbi Luca
Grether Uwe
Kimbara Atsushi
Nettekoven Matthias
Rogers-Evans Mark
Schulz-Gasch Tanja
Roever Stephan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR093843A1 publication Critical patent/AR093843A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1) en la que: R¹ es halógeno, cicloalquilalcoxi, haloalcoxi, alquilsulfonilo, alquilsulfinilo, halofenilalquilo, alquilsulfanilo, oxanilalcoxi, halofenilo u oxolanilalcoxi; R² es halógeno, cicloalquilo, haloalquilo, haloalcoxi, haloazetidinilo, cicloalquiloxi, halocicloalquilo, hidroxicicloalquilo, hidroxiazetidinilo, hidroxioxetanilo o halooxetanilo; R³ es (alquil)(oxo)pirrolidinilo o -C(R⁴R⁵)-C(R⁶R⁷)-C(O)-R⁸; R⁴ y R⁵ se eligen con independencia entre hidrógeno, alquilo, fenilo, fenilalquilo, cicloalquilo, tetrahidropiranilo, haloalquilo, halofenilo y oxolanilo; o R⁴ y R⁵ junto con el átomo de carbono al que están unidos forman un cicloalquilo, oxetanilo, tietanilo, 1,1-dioxo-1l6-tietanilo, azetidinilo, haloazetidinilo, 2-oxa-espiro[3.3]-heptilo, tetrahidrofuranilo, pirrolidinilo, oxopirrolidinilo, 1,1-dioxo-1l6-isotiazolidinilo, 1,1-dioxo-tetrahidro-1l6-tiofenilo, tetrahidrotiofenilo, tetrahidropiranilo, piperidinilo, oxopiperidinilo, tetrahidrotiopiranilo, 2-oxo-[1,3]-oxazinanilo, 1,1-dioxo-1l6-[1,2]tiazinanilo, 2-oxo-hexahidro-pirimidinilo, 1,1-dioxo-hexahidro-1l6-tiopiranilo, 2-oxo-[1,3]dioxanilo, 1,1-dioxotianilo, alquilcarbonilpiperidinilo, alquilcarbonilazetidinilo, fenilalquiloxicarbonilazetidinilo, oxolanilo o fenilalquiloxicarbonilpirrolidinilo; R⁶ y R⁷ se eligen con independencia entre hidrógeno y alquilo; o uno de R⁴ y R⁵ y uno de R⁶ y R⁷, junto con el átomo de carbono al que están unidos forman un cicloalquilo, y los restantes son en ambos casos hidrógeno al mismo tiempo; y R⁸ es -NH₂, alcoxi, alquilamino o hidroxilo; o una sal o un éster farmacéuticamente aceptable del mismo.
ARP130104545A 2012-12-07 2013-12-06 Derivados de piridina agonistas de receptores cb2 AR093843A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12196022 2012-12-07

Publications (1)

Publication Number Publication Date
AR093843A1 true AR093843A1 (es) 2015-06-24

Family

ID=47290804

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104545A AR093843A1 (es) 2012-12-07 2013-12-06 Derivados de piridina agonistas de receptores cb2

Country Status (34)

Country Link
US (1) US9522886B2 (es)
EP (2) EP3357918A1 (es)
JP (1) JP6426618B2 (es)
KR (1) KR20150092282A (es)
CN (2) CN107674061A (es)
AR (1) AR093843A1 (es)
AU (2) AU2013354278B2 (es)
BR (1) BR112015012919A2 (es)
CA (1) CA2890100A1 (es)
CL (1) CL2015001536A1 (es)
CO (1) CO7350620A2 (es)
CR (1) CR20150250A (es)
DK (1) DK2928881T3 (es)
EA (1) EA026669B1 (es)
ES (1) ES2668690T3 (es)
HK (1) HK1208031A1 (es)
HR (1) HRP20180672T1 (es)
HU (1) HUE036911T2 (es)
IL (1) IL239075B (es)
LT (1) LT2928881T (es)
MA (1) MA38239A1 (es)
MX (1) MX2015007155A (es)
NO (1) NO2928881T3 (es)
PE (1) PE20151025A1 (es)
PH (1) PH12015501083A1 (es)
PL (1) PL2928881T3 (es)
PT (1) PT2928881T (es)
RS (1) RS57143B1 (es)
SG (2) SG10201800170YA (es)
SI (1) SI2928881T1 (es)
TW (1) TWI600645B (es)
UA (1) UA114656C2 (es)
WO (1) WO2014086705A1 (es)
ZA (1) ZA201503969B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2629751T3 (es) 2013-03-07 2017-08-14 F. Hoffmann-La Roche Ag Derivados de pirazol novedosos
EA027569B1 (ru) 2013-03-26 2017-08-31 Ф.Хоффманн-Ля Рош Аг Производные пиридина
RS57461B1 (sr) 2013-05-02 2018-09-28 Hoffmann La Roche Derivati purina kao agonisti cb2 receptora
UA116801C2 (uk) 2013-05-02 2018-05-10 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2
KR20220140651A (ko) 2013-09-06 2022-10-18 에프. 호프만-라 로슈 아게 신규의 트라이아졸로[4,5-d]피리미딘 유도체
PE20161407A1 (es) * 2014-04-04 2016-12-28 Hoffmann La Roche Piridina 5,6 disustituida -2-carboxamidas como agonistas del receptor canabinoide
EP3156397B1 (en) 2014-06-13 2019-08-07 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
CA2999216A1 (en) * 2015-12-09 2017-06-15 F. Hoffmann-La Roche Ag Phenyl derivatives as cannabinoid receptor 2 agonists
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018234284A1 (en) 2017-06-20 2018-12-27 F. Hoffmann-La Roche Ag PYRIDINE DERIVATIVES
WO2019201718A1 (en) * 2018-04-18 2019-10-24 Basf Se D-glucaro-6,3-lactone monoester and a process for the preparation thereof
WO2020002280A1 (en) * 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
WO2020002270A1 (en) 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
CN112638430B (zh) 2018-06-27 2023-05-16 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
CN114502538A (zh) * 2019-09-30 2022-05-13 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的经取代的3,4-二氢喹唑啉
WO2022053651A2 (en) 2020-09-10 2022-03-17 Precirix N.V. Antibody fragment against fap
US20220348568A1 (en) * 2021-04-19 2022-11-03 Chemocentryx, Inc. Azetidinyl-acetamides as cxcr7 inhibitors
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344128T3 (es) * 2006-10-04 2010-08-18 F. Hoffmann-La Roche Ag Derivados de pirazina-2-carboxamida como moduladores de receptores cb2.
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
AR085013A1 (es) * 2011-01-26 2013-08-07 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor

Also Published As

Publication number Publication date
CA2890100A1 (en) 2014-06-12
UA114656C2 (uk) 2017-07-10
HUE036911T2 (hu) 2018-08-28
RS57143B1 (sr) 2018-07-31
JP2016501240A (ja) 2016-01-18
CL2015001536A1 (es) 2015-10-23
CO7350620A2 (es) 2015-08-10
EP3357918A1 (en) 2018-08-08
DK2928881T3 (en) 2018-05-28
AU2017279648A1 (en) 2018-01-18
SI2928881T1 (en) 2018-07-31
PH12015501083B1 (en) 2015-08-03
BR112015012919A2 (pt) 2017-07-11
HRP20180672T1 (hr) 2018-06-01
CR20150250A (es) 2015-06-11
PH12015501083A1 (en) 2015-08-03
SG10201800170YA (en) 2018-02-27
CN107674061A (zh) 2018-02-09
US20150307452A1 (en) 2015-10-29
WO2014086705A1 (en) 2014-06-12
KR20150092282A (ko) 2015-08-12
JP6426618B2 (ja) 2018-11-21
PE20151025A1 (es) 2015-07-15
PT2928881T (pt) 2018-05-07
MX2015007155A (es) 2015-10-14
TWI600645B (zh) 2017-10-01
CN104837831A (zh) 2015-08-12
MA38239A1 (fr) 2017-03-31
EP2928881B1 (en) 2018-03-14
IL239075A0 (en) 2015-07-30
EA026669B1 (ru) 2017-05-31
AU2013354278A1 (en) 2015-05-14
HK1208031A1 (en) 2016-02-19
AU2013354278B2 (en) 2017-10-12
US9522886B2 (en) 2016-12-20
ES2668690T3 (es) 2018-05-21
ZA201503969B (en) 2016-04-28
PL2928881T3 (pl) 2018-07-31
IL239075B (en) 2018-11-29
LT2928881T (lt) 2018-06-11
SG11201504416XA (en) 2015-07-30
EP2928881A1 (en) 2015-10-14
CN104837831B (zh) 2017-10-31
NO2928881T3 (es) 2018-08-11
TW201427951A (zh) 2014-07-16
EA201591064A1 (ru) 2015-09-30

Similar Documents

Publication Publication Date Title
AR093843A1 (es) Derivados de piridina agonistas de receptores cb2
AR095721A1 (es) Derivados de piridina
AR093805A1 (es) Derivados de piridina agonistas del receptor 2 de cannabinoides
AR099932A1 (es) Derivados de piridina
AR094621A1 (es) Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
AR102539A1 (es) Triazolo[4,5-d]pirimidinas
AR069480A1 (es) Derivados de 2-amino-pirimidina
AR063723A1 (es) 5-oxo-5,8-dihidro-piridopirimidinas inhibidoras de c-fms quinasas, composiciones farmaceuticas que las contienen y usos como agentes anticancer, en enfermedades cardiovasculares y procesos inflamatorios
PE20171789A1 (es) Inhibidores del factor beta de crecimiento de transformacion (tgf-beta)
AR091781A1 (es) Antagonistas del receptor de 5-ht3
UY30387A1 (es) Nuevos compuestos
AR088969A1 (es) Derivados de pirrolidina
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
WO2014117076A8 (en) Alkyl aromatic hydroalkylation for the production of plasticizers
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
ES2531274T3 (es) Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
AR090966A1 (es) Picolinamidas macrociclicas como fungicidas
AR076666A1 (es) Derivados azabiciclicos como inhibidor de hsl (lipasa sensible a las hormonas)
CO6160237A2 (es) Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
AR074504A1 (es) Nucleotidos uracil ciclopropilicos
AR121985A1 (es) Compuestos de azalactama como inhibidores de hpk1
AR094978A1 (es) Derivados de pirazol agonistas de receptores canabinoides
CO6160307A2 (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas
AR093804A1 (es) Derivados de pirazina agonistas de receptores cb2

Legal Events

Date Code Title Description
FB Suspension of granting procedure